Targeted protein degradation (TPD) is emerging to be a promising technology for targeting disease-causing proteins. Through the mechanism of hijacking either the ubiquitin-proteasome system (UPS) or the autophagy-lysosomal pathway the protein of interest is degraded,...

Learn more about Origami, one of Biocenturys 2021 class of emerging companies.

See the BioTech Showcase Agenda

The Huntington’s Disease Society of America (HDSA) is proud to announce that Jeff Carroll, PhD and Beth Hoffman, PhD have been elected to the Society’s National Board of Trustees. Learn More

Learn about the Panelists

Origami Therapeutics developing treatments for neurodegenerative diseases with ML and computational chemistry. Learn more

View the presentation

Emerging Company Profile – Origami: Correcting or eliminating misfolded proteins. Learn More

Presenting Company event information  

Click to learn more

Presentation: Triaging Your Drug Targets to Find the Most Relevant Lead (CEO Beth Hoffman) https://www.hub-xchange.com/cns-therapeutics-xchange-west-coast-2021/#anchor1

The Tau Consortium is a collaborative research program that is managed and funded by the Rainwater Charitable Foundation in partnership with other funders. Read More

SAN DIEGO, May 4, 2021 /PRNewswire/ -- Origami Therapeutics http://origamitherapeutics.com,a discovery-stage company taking a precision medicine approach to discover diseasemodifyingtreatments for neurodegeneration, announced today it has been selected as one of13...

LABEST 2021 Full Agenda 5.17

Catch up on all of the latest updates from day 2 of the 2021 CHDI Huntington’s disease therapeutics conference #HDTC2021 Watch the video Read more

Arctoris appoints three experienced industry executives as members of its Advisory Board. Read Article

Official Event Guide- Digital Protein Misfolding Drug Discovery Summit- Hanson Wade

The Awardees for the SVB pitch contest last fall: See Awardees Also learn more with: A Glimpse Into the Mind of the Investor